WeTrials
Recruiting

Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell Transplant

What is this study?

This study is testing a special combination of medications to help prevent a common and serious complication after a stem cell transplant called graft-versus-host disease, where donor cells attack the patient's body. By finding better ways to prevent this, the study aims to make stem cell transplants safer and more effective for patients with blood cancers and bone marrow disorders.

Who can participate?

Adults between 18 and 60 years old who are scheduled to receive a stem cell transplant from a matching donor may be able to join. Participants also need to meet specific health requirements regarding their heart, kidneys, and overall physical strength.

What will happen?

Participants will receive a combination of immune-suppressing drugs, including a specific dosing schedule of a medication called ATG, along with tacrolimus and a low dose of chemotherapy called methotrexate around the time of their stem cell transplant. Your medical team will closely monitor your health, recovery, and any side effects throughout the process.

Where and when?

This study is currently recruiting participants and takes place in Birmingham, Alabama, United States.

Key Points
  • 1The study tests a new medication combination to prevent graft-versus-host disease after a stem cell transplant.
  • 2It is open to adults aged 18 to 60 with a matching stem cell donor.
  • 3The study is currently active and recruiting participants in Birmingham, Alabama.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
GVHD,AcuteAcute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.